These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 526003)

  • 1. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.
    Smyth RD; Pfeffer M; Glick A; Van Harken DR; Hottendorf GH
    Antimicrob Agents Chemother; 1979 Nov; 16(5):615-21. PubMed ID: 526003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.
    Lee FH; Pfeffer M; Van Harken DR; Smyth RD; Hottendorf GH
    Antimicrob Agents Chemother; 1980 Feb; 17(2):188-92. PubMed ID: 7387141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative tissue distribution of ceforanide, cefazolin, and cefamandole in rats.
    Lee FH; Smyth RD; Van Harken DR
    Antimicrob Agents Chemother; 1981 Apr; 19(4):625-7. PubMed ID: 7247385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ceforanide.
    Ripa S; La Rosa F; Ghezzi A; Prenna M; Pfeffer M
    Antimicrob Agents Chemother; 1982 Feb; 21(2):323-6. PubMed ID: 7073268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceforanide kinetics in renal insufficiency.
    Hawkins SS; Alford RH; Stone WJ; Smyth RD; Pfeffer M
    Clin Pharmacol Ther; 1981 Oct; 30(4):468-74. PubMed ID: 7285481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents.
    Dajani AS; Thirumoorthi MC; Bawdon RE; Buckley JA; Pfeffer M; Van Harken DR; Smyth RD
    Antimicrob Agents Chemother; 1982 Feb; 21(2):282-7. PubMed ID: 7073266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.
    Hess JR; Berman SJ; Boughton WH; Sugihara JG; Musgrave JE; Wong EG; Siemsen AM
    Antimicrob Agents Chemother; 1980 Feb; 17(2):251-3. PubMed ID: 7387145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide.
    Pfeffer M; Gaver RC; Van Harken DR
    J Pharm Sci; 1980 Apr; 69(4):398-403. PubMed ID: 7373533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects.
    Scheld WM; Spyker DA; Donowitz GR; Bolton WK; Sande MA
    Antimicrob Agents Chemother; 1981 Apr; 19(4):613-9. PubMed ID: 6454387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraoperative ceforanide pharmacokinetics and protein binding.
    DiPiro JT; Bayoumi SM; Vallner JJ; Nesbit RR; Gokhale R; Rissing JP
    Antimicrob Agents Chemother; 1985 Apr; 27(4):487-90. PubMed ID: 4004190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic study of cefazaflur compared to cephalothin and cefazolin.
    Harvengt C; Muenier H; Lamy F
    J Clin Pharmacol; 1977; 17(2-3):128-33. PubMed ID: 833342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion.
    Polk RE; Kline BJ; Markowitz SM
    Antimicrob Agents Chemother; 1981 Nov; 20(5):576-9. PubMed ID: 6459759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women.
    Philipson A; Stiernstedt G; Ehrnebo M
    Clin Pharmacokinet; 1987 Feb; 12(2):136-44. PubMed ID: 3829560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal tubular mechanisms for excretion of cefpiramide (SM-1652) in association with its long-lasting pharmacokinetic properties.
    Matsui H; Okuda T
    J Pharmacobiodyn; 1988 Feb; 11(2):67-73. PubMed ID: 3379566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. II. Pharmacokinetics in comparison with cefazolin.
    Pabst J; Leopold G; Ungethüm W; Dingeldein E
    Arzneimittelforschung; 1979; 29(2a):437-43. PubMed ID: 582722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of pharmacokinetics.
    Cutler RE
    Rev Infect Dis; 1984; 6 Suppl 4():S803-8. PubMed ID: 6522921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative bactericidal effect of ceforanide (BL-S 786) and five other cephalosporins in an in vitro pharmacokinetic model.
    Randolph JA; Buck RE; Price KE; Leitner F
    J Antibiot (Tokyo); 1979 Jul; 32(7):727-33. PubMed ID: 396292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefazolin in patients with renal failure; special reference to hemodialysis.
    Brogard JM; Pinget M; Brandt C; Lavillaureix J
    J Clin Pharmacol; 1977 Apr; 17(4):225-30. PubMed ID: 849996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption, distribution and elimination of cefazolin in patients with normal renal function.
    Bergan T; Digranes A; Schreiner A
    Chemotherapy; 1978; 24(5):277-82. PubMed ID: 352636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage adjustments of cefazolin according to the pharmacokinetics of this new cephalosporin.
    Lavillaureix J; Brogard JM; Pinget M; Ledoux F
    Infection; 1975; 3(2):105-14. PubMed ID: 1102452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.